Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. [electronic resource] - The New England journal of medicine Oct 2008 - 1786-801 p. digital

Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1533-4406

10.1056/NEJMoa0802670 doi


Adjuvants, Immunologic--adverse effects
Adolescent
Adult
Alemtuzumab
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm--adverse effects
Autoimmune Diseases--chemically induced
Female
Humans
Infections--chemically induced
Interferon beta-1a
Interferon-beta--adverse effects
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting--drug therapy
Purpura, Thrombocytopenic--chemically induced
Thyroid Diseases--chemically induced
Treatment Outcome